Psychedelics like psilocybin, MDMA, and ketamine are emerging as promising therapeutic tools for mental health issues. Here's ...

People suffering from major depressive disorder (MDD) and treatment-resistant depression (TRD) often face challenging ...

Proven Success for Treatment-Resistant Conditions Many individuals in NYC have turned to ketamine therapy ... These options ...

Learn more about how an anesthetic traditionally used for surgical procedures may help depression and what to expect during ...

Over 600,000 people worldwide die from mosquito-borne malaria each year, with the majority of these deaths happening among ...

Atai Life Sciences N.V. ( (ATAI) ) has released its Q3 earnings. Here is a breakdown of the information Atai Life Sciences N.V. presented to ...

Long-term inpatient treatment is suitable for individuals who require extended care due to chronic or treatment-resistant ...

The United States Food and Drug Administration cleared the investigational new drug application for VLS-01 (buccal film DMT); ...

By targeting complex conditions such as treatment-resistant depression, social anxiety disorder and opioid use disorder, Atai aims to address significant gaps in the mental health treatment landscape.

Epilepsy is a chronic brain condition where nerve cells in the brain send incorrect signals causing seizures Heres how it ...

The company is set to begin Phase 2 trials for VLS-01 in treatment-resistant depression and EMP-01 for social anxiety disorder by the end of 2024. With FDA clearance for VLS-01 and a strategic ...

MIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a preclinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic ...